Literature DB >> 2453013

Alternative splicing of human p53 transcripts.

G Matlashewski1, D Pim, L Banks, L Crawford.   

Abstract

The human p53 gene is expressed in both normal and transformed human cells as a family of polypeptides. One type of heterogeneity, which results in variation in electrophoretic mobility, is found at amino acid residue 72 (Matlashewski et al, 1987). A second type of heterogeneity is described here which involves an alteration in the sequence of the open reading frame at the 5' end of the p53 mRNA. This heterogeneity is generated by alternative splicing at the acceptor site in intron 2 resulting in an altered 5' end coding region. This study represents the first description of an altered human p53 transcript arising by differential splicing.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2453013

Source DB:  PubMed          Journal:  Oncogene Res        ISSN: 0890-6467


  11 in total

1.  The history of p53. A perfect example of the drawbacks of scientific paradigms.

Authors:  Thierry Soussi
Journal:  EMBO Rep       Date:  2010-10-08       Impact factor: 8.807

2.  Alternative splicing within the chicken c-ets-1 locus: implications for transduction within the E26 retrovirus of the c-ets proto-oncogene.

Authors:  D Leprince; M Duterque-Coquillaud; R P Li; C Henry; A Flourens; B Debuire; D Stehelin
Journal:  J Virol       Date:  1988-09       Impact factor: 5.103

3.  Alternative splicing of RNAs transcribed from the chicken c-mil gene.

Authors:  C Dozier; F Denhez; C Henry; J Coll; A Begue; B Quatannens; S Saule; D Stehelin
Journal:  Mol Cell Biol       Date:  1988-04       Impact factor: 4.272

4.  p53 isoform profiling in glioblastoma and injured brain.

Authors:  R Takahashi; C Giannini; J N Sarkaria; M Schroeder; J Rogers; D Mastroeni; H Scrable
Journal:  Oncogene       Date:  2012-07-23       Impact factor: 9.867

Review 5.  p53 Isoforms as Cancer Biomarkers and Therapeutic Targets.

Authors:  Liuqun Zhao; Suparna Sanyal
Journal:  Cancers (Basel)       Date:  2022-06-27       Impact factor: 6.575

6.  Species- and tissue-specific expression of the C-terminal alternatively spliced form of the tumor suppressor p53.

Authors:  K Will; G Warnecke; S Bergmann; W Deppert
Journal:  Nucleic Acids Res       Date:  1995-10-25       Impact factor: 16.971

7.  Regulation of human p53 activity and cell localization by alternative splicing.

Authors:  Anirban Ghosh; Deborah Stewart; Greg Matlashewski
Journal:  Mol Cell Biol       Date:  2004-09       Impact factor: 4.272

8.  The p53 isoforms are differentially modified by Mdm2.

Authors:  Suzanne Camus; Sergio Ménendez; Kenneth Fernandes; Nelly Kua; Geng Liu; Dimitris P Xirodimas; David P Lane; Jean-Christophe Bourdon
Journal:  Cell Cycle       Date:  2012-04-15       Impact factor: 4.534

Review 9.  Biological functions of p53 isoforms through evolution: lessons from animal and cellular models.

Authors:  V Marcel; M-L Dichtel-Danjoy; C Sagne; H Hafsi; D Ma; S Ortiz-Cuaran; M Olivier; J Hall; B Mollereau; P Hainaut; J-C Bourdon
Journal:  Cell Death Differ       Date:  2011-09-23       Impact factor: 15.828

10.  Δ40p53 isoform up-regulates netrin-1/UNC5B expression and potentiates netrin-1 pro-oncogenic activity.

Authors:  Yan Sun; Ambroise Manceau; Lisa Frydman; Lucie Cappuccio; David Neves; Valeria Basso; Hong Wang; Joanna Fombonne; Carine Maisse; Patrick Mehlen; Andrea Paradisi
Journal:  Proc Natl Acad Sci U S A       Date:  2021-09-07       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.